SCHEMBL3230261

SCHEMBL3230261

C[Si](C)(C)OC(c1ccccc1)(c1noc(CCl)n1)C1CCCCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.35
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
POLB P06746 3/20 0.32
CASP3 P42574 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32
CHRM3 P20309 4/20 0.32
CHRM2 P08172 5/20 0.32
CHRM1 P11229 5/20 0.32
CYP2D6 P10635 3/20 0.32
KCNH2 Q12809 3/20 0.32
NPC1 O15118 1/20 0.31
NPSR1 Q6W5P4 1/20 0.30
MEN1 O00255 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30
CHRM4 P08173 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3230254 1.00 RAB9A (0.35) RAB9AALDH1A1L3MBTL1POLBCASP3
SCHEMBL3210000 0.80 CHRM3 (0.43) RAB9AALDH1A1L3MBTL1CHRM3CHRM2
SCHEMBL1845152 0.77 CHRM2 (0.32) POLBCHRM3CHRM2CHRM1CYP2D6
SCHEMBL1845153 0.77 CHRM2 (0.32) POLBCHRM3CHRM2CHRM1CYP2D6
SCHEMBL3223141 0.68 SLC6A2 (0.36) RAB9AALDH1A1L3MBTL1CHRM3CYP2D6
SCHEMBL4740717 0.68 CHRM3 (0.43) RAB9AALDH1A1L3MBTL1CHRM3CHRM2
SCHEMBL4727371 0.68 CHRM3 (0.43) RAB9AALDH1A1L3MBTL1POLBCHRM3
SCHEMBL20176049 0.63 MEN1 (0.36) ALDH1A1POLBCHRM3CHRM2CHRM1
SCHEMBL1315214 0.62 KEAP1 (0.44) ALDH1A1L3MBTL1POLBCHRM3CHRM2
SCHEMBL9809468 0.62 KEAP1 (0.46) ALDH1A1POLBCHRM3CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010018352-A1 HETEROCYCLIC COMPOUNDS USED IN THE TREATMENT OF DISEASES WHERE ENHANCED M3 RECEPTOR ACTIVATION IS IMPLICATED ARGENTA DISCOVERY LIMITED (GB) 2010-02-18 WO disclosed